Zlecone: Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA(R) (Edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism After Major Orthopedic Surgery
TOKYO, April 22, 2011 /PRNewswire/ - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that the company has received its first marketing approval for LIXIANA(R) (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan.